Effectiveness of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) for the treatment of larval and immature adult stages of Ancylostoma caninum in experimentally infected dogs

Table 1 Effectiveness of a single oral dose of a novel chewable tablet (Credelio Plus) containing milbemycin oxime and lotilaner against induced L4 larval and immature adult (L5) Ancylostoma caninum infections in dogs

Study	Stage at time of treatment	Day of inoculation ^a	Day of treatment	Day of necropsy (worm recovery)	Treatment group	n	No. of infected dogs	Worm count range	Geometric worm count	Effectiveness compared to vehicle control
Study	Stage at time of treatment	Day of inoculation ^a	Day of treatment	Day of necropsy (worm recovery)	Treatment group	n	No. of infected dogs	Worm count range	Geometric worm count	% efficacy	Effectiveness P-value
1	L4 Larvae	0	7	12	Vehicle control	8	8	60–248	171.9	–	–
					Credelio Plus^b	8	8	1–15	4.6	97.3	P < 0.001
					Credelio^c	8	8	98–236	171.7	0.1	P < 0.001
2	L4 Larvae	0	7	12	Vehicle control	10	10	42–156	79.4	–	–
					Credelio Plus^b	10	3	0–2	0.3	99.6	P < 0.001
1	Immature adult (L5)	0	11	16	Vehicle control	8	8	173–255	198.7	–	–
					Credelio Plus^b	8	6	0–86	2.5	98.7	P < 0.001
					Credelio^c	8	8	149–231	178.8	10.0	P < 0.001
2	Immature adult (L5)	0	11	16	Vehicle control	10	10	61–302	109.7	–	–
					Credelio Plus^b	10	2	0–3	0.3	99.7	P < 0.001

n Number of animals per group
^aEach dog was inoculated with ca. 300 L3 A. caninum
^bCredelio Plus provided minimum dosages of 0.845 to 0.943 mg/kg of milbemycin oxime in both studies
^cCredelio™ (lotilaner mono product) was included in study 1 to assess non-interference

ISSN: 1756-3305